EAM
AKBA icon

Empirical Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Empirical Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.6K Hold
35,000
– – 0.01% 396
2025
Q4 		$56.4K Buy
35,000
+15,000
+75% +$31.4K 0.02% 345
2025
Q3 		$54.6K Buy
+20,000
New +$66.5K 0.02% 358
2025
Q2 		– Sell
-10,000
Closed -$19.2K – 315
2025
Q1 		$19.2K Sell
10,000
-3,300
-25% -$6.74K 0.01% 300
2024
Q4 		$25.3K Sell
13,300
-20,400
-61% -$35.4K 0.01% 414
2024
Q3 		$44.5K Buy
+33,700
New +$45K 0.02% 292

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Empirical Asset Management's AKBA Position: Q1 2026 in Review

Empirical Asset Management held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 35,000 shares worth $48.6K. The position accounts for 0.01% of the portfolio, ranked #396.

Empirical Asset Management first reported a position in AKBA in Q3 2024 and has held it in 6 quarters since. The position peaked at $56.4K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Empirical Asset Management held 35,000 shares of Akebia Therapeutics worth $48.6K as of Q1 2026.
  • Empirical Asset Management left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up 0.01% of Empirical Asset Management's portfolio in Q1 2026, its #396 holding.
  • Empirical Asset Management first reported a position in Akebia Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Empirical Asset Management's Akebia Therapeutics position peaked at $56.4K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Empirical Asset Management's 13F filing for Q1 2026, filed 11 May 2026.